

Supporting Information

Enhanced nuclear accumulation of pyrrole-imidazole polyamides by incorporation of the tri-arginine vector

Takuya Hidaka,^a Yutaro Tsubono,^a Kaori Hashiya,^a Toshikazu Bando,^a Ganesh N. Pandian,^b Hiroshi Sugiyama^{*ab}

[†] Department of Chemistry, Graduate School of Science, Kyoto University, Sakyo, Kyoto 606-8502, Japan

[‡] Institute for Integrated Cell-Material Science (WPI-iCeMS), Kyoto University, Sakyo, Kyoto 606-8501, Japan.

Table of contents	Page
Experimental methods	S1 – S4
(Figure S1) Relative RNA expression level of SOX2 downstream genes in 201B7 cells treated with SOX2i and SOX2i-R3	S5
(Figure S2) Transcription control of <i>HER2</i> by AP2i-R3	S6
(Figure S3) Characterization data of synthesized compounds	S7 – S13
(Table S1) Primers used for qPCR	S14
References	S15

Experimental methods

General information of synthesis

The reagents were purchased from standard suppliers. The solid phase synthesis was performed using an automated synthesizer PSSM-8 (Shimadzu) with a computer assisted operation system. Reversed-phase high performance liquid chromatography (HPLC) was performed on a JASCO HPLC system (JASCO Engineering UV2075 UV/vis detector and a PU-2089 plus gradient pump) equipped with Chemcobond 5-ODS-H reversed-phase column (4.6 × 150 mm). H₂O (+0.1% trifluoroacetic acid) and acetonitrile were used as the mobile phase and the program was a linear gradient of 0 to 100% acetonitrile in 40 min at a flow rate of 1.0 mL/min. Absorbance at 254 nm was monitored. MALDI-TOF mass spectroscopy was performed with the microflex system (Bruker).

Synthesis of SOX2i-R3, SOX2i, Ctrl-R3, AP2i-R3 and AP2i

The Fmoc solid-phase synthesis was performed as described previously.^{1,2} Each Fmoc monomer units (Fmoc-D-Arg(Pbf)-OH, Fmoc-β-alanine-OH, Fmoc-GABA-OH, Fmoc-*N*-methylpyrrole (Py)-OH and Fmoc-*N*-methylimidazole (Im)-OH) was introduced sequentially to Fmoc-D-Arg(Pbf)-Alko resin for synthesis of SOX2i-R3, Ctrl-R3 and AP2i-R3 and to PyIm-coupled clear resin or Im-coupled oxime resin for synthesis of SOX2i and AP2i, respectively. Fmoc-ImPy-OH dimer units were also used in the synthesis of SOX2i-R3 to improve the synthesis efficiency. N-terminal was capped with acetyl group by mixing with 20% acetic anhydride in *N,N*-dimethylformamide. Synthesized compounds were cleaved with *N,N*-dimethylaminopropylamine at 55 °C for 3 hours. The reaction solution was drained into ether and the resulting solid was dried *in vacuo*. Protecting group of arginine residues (Pbf group) of SOX2i-R3, Ctrl-R3 and AP2i-R3 were removed with deprotection cocktail (trifluoroacetic acid: triisopropylsilane: water (95:2.5:2.5 v/v%)) at room temperature for 30 minutes. The crude sample was purified by reversed-phase HPLC using a JASCO HPLC system (JASCO Engineering UV2075 UV/vis detector and a PU-2089 plus gradient pump) with a preparative C18 (ODS) column (COSMOSIL 5C₁₈-MS-II, 10ID × 150 mm). H₂O (+0.1% trifluoroacetic acid) and acetonitrile were used as the mobile phase. HPLC and MALDI-TOF mass spectroscopy was performed for the characterization of the purified compounds.

Synthesis of SOX2i-R3-TAMRA and SOX2i-TAMRA

After the solid phase synthesis, the compounds were cleaved from the resin with 3, 3'-diamino-*N*-methylpropylamine at 55 °C for 3 hours. The crude samples were purified by reversed-phase column chromatography using the CombiFlash Rf system equipped with 4.3 g C18 RediSep Rf reversed-phase flash column (Teledyne Isco, Inc). H₂O (+0.1% trifluoroacetic acid) and acetonitrile were used as the mobile phase. The coupling reaction was performed by adding 1.3 eq of 5-TAMRA-NHS ester and 3 eq of *N,N*-diisopropylethylamine (DIEA) and shaking at room temperature overnight. Powderization, deprotection, purification and characterization were performed as described above.

Cell culture

HeLa (JCRB9004) and 201B7 cells were provided by JCRB Cell Bank (Japan) and the RIKEN BRC (Japan) respectively. SKBR-3 cells were purchased from ATCC. All cells were maintained in a humidified CO₂ incubator at 37°C.

HeLa cells were maintained in Dulbecco's Modified Eagle Medium (ThermoFisher Scientific) supplemented with 10 % fetal bovine serum (Sigma) and 1% MEM Non-Essential Amino Acids Solution (ThermoFisher Scientific).

201B7 iPS cells were cultured on Matrigel Matrix (hESC-qualified, Corning) in mTeSR1 medium (Stemcell Technologies) supplemented with 0.5x penicillin/streptomycin (Nacalai Tesque). Cells were passaged using TrypLE Express Enzyme (no phenol red, ThermoFisher Scientific) as dissociation reagent and seeded in medium supplemented with 2.5 μM of Y-27632 (Wako). Medium change with fresh medium (without Y-27632) was performed every day from the next day of the passaging.

SKBR-3 cells were maintained in McCoy's 5A Medium (ThermoFisher Scientific) supplemented with 10 % fetal bovine serum (Sigma).

Live cell imaging

Exponentially growing HeLa cells were trypsinized and seeded on 8-well ibi-treat μ-slides (ibidi) at the density of 1.5×10^4 cells/ well one day prior to the treatment. DMSO solution of SOX2i-R3-TAMRA and SOX2i-TAMRA was prepared and the concentration was determined using an extinction coefficient of $91000 \text{ M}^{-1} \text{ cm}^{-1}$ at λ_{max} near 565 nm. The medium was changed with OPTI-MEM (ThermoFisher Scientific) containing 2% FBS (Sigma) and 5 μM of each compound (DMSO: 0.5%) and cells were treated for 24 hours. After the treatment, the culture medium was removed and FluoroBrite DMEM (ThermoFisher Scientific) supplemented with 10% FBS (Sigma) and Hoechst33342 (1 μg/mL) was added and incubated for 10 minutes. Cells were washed twice with FluoroBrite DMEM and imaged by the FV1200 Laser Scanning Microscope (Olympus). The same imaging conditions were adopted for all samples. Image analysis was performed using FV10-ASW (Olympus).

Flow cytometry analysis

Exponentially growing HeLa cells were trypsinized and seeded on a 12-well plate (NIPPON Genetics) at the concentration of 5×10^4 cells/ well one day prior to the treatment. The medium was changed with OPTI-MEM (ThermoFisher Scientific) containing 2% FBS (Sigma) and 5 μM of each compound (DMSO: 0.5%) and the treatment was performed for 24 hours. After the treatment, the cells were detached from the plate by trypsinization and subjected to D-PBS wash twice. The washed cells were resuspended in D-PBS. Samples were analyzed using a BD FACS AriaII (BD Biosciences) after removal of cell clumps using polystyrene tubes with cell strainer caps (Corning). 20000 events were recorded for each sample, and FSC (Forward Scatter)/ SSC (Side Scatter) plot was used for population gating to remove data points obtained from debris and electrical noise. After the selection, signal intensity of TAMRA of 13,082 events of the negative control

sample, 12,330 events of the SOX2i-R3-TAMRA treated sample and 13,834 events of the SOX2i-TAMRA treated sample were plotted in the histogram.

Electrophoretic mobility shift assay

DMSO solution of SOX2i-R3, SOX2i and Ctrl-R3 was prepared and the concentration was determined from the calculation formula below using the maximum absorbance in 300-310 nm measured by a Nanodrop ND-1000 (ThermoFisher Scientific):

$$c = \frac{Abs}{9900 \times a \times d} (M)$$

(a: total number of pyrrole and imidazole rings, d (cm): optical path length (0.1 cm for Nanodrop ND-1000), Abs = Maximum absorbance in 300-310 nm)

Each template DNA (1 μ M) was mixed with 1 μ M of SOX2i-R3, SOX2i or Ctrl-R3 in aqueous buffer containing 10 mM sodium chloride, 10 mM sodium cacodylate and 2.5 v/v% DMSO at pH 7.0. Before electrophoresis samples were annealed by heating to 95°C for 3 min and cooled to 25°C at speed of -0.5°C/5 seconds. 8 μ L of each sample was mixed with 2 μ L of Novex Hi-Density TBE Sample Buffer (ThermoFisher Scientific) and 1 μ L of each loading mixture was loaded. Native-PAGE was performed with 20% polyacrylamide gel at 200 V for 60 min in TBE buffer. The gel was stained with SYBR Gold (ThermoFisher Scientific) and imaged with the FLA-3000 system (Fujifilm).

Quantitative reverse-transcription PCR (RT-qPCR) analysis of 201B7 cells

201B7 iPS cells were seeded on a Matrigel-coated 24-well plate (Greiner) in mTeSR1 medium supplemented with 2.5 μ M of Y-27632 at the concentration of 6×10^4 cells/ well one day prior to the treatment. The medium was replaced with differentiation medium (Advanced RPMI 1640 (ThermoFisher Scientific) supplemented with 0.2% FBS and 1x L-glutamine) containing each compound and 0.1% DMSO. 48 hours later, total RNA was extracted from each well using FastGene RNA Basic Kit (NIPPON Genetics) and reverse transcription was performed from 500 ng of total RNA using ReverTra Ace qPCR RT Master Mix with gDNA Remover (Toyobo) following the manufacturer's instructions. Reaction mixture was prepared with Thunderbird SYBR qPCR mix (Toyobo) and qPCR reaction was performed and monitored on LightCycler 480 System II (Roche). The relative expression level of each gene was calculated from the average Cp value of three replicates of each samples and normalized to the mean value of negative control samples. The primer pairs used in this experiment are listed in Table S1.

Quantitative reverse-transcription PCR (RT-qPCR) analysis of SKBR-3 cells

SKBR-3 cells were seeded on a 12-well plate (Greiner) in growth medium at the concentration of 1×10^5 cells/ well one day prior to the treatment. The medium was replaced with fresh growth medium containing each compound and 0.1% DMSO and the cells were treated for 48 hours. The successive RNA extraction, reverse transcription and qPCR assay were performed as explained above.




Figure S1. Relative RNA expression level of SOX2 downstream genes in 201B7 cells treated with SOX2i and SOX2i-R3 for 48 hours. Mean values calculated from three culture wells are indicated as a bar chart. Each value is normalized to the control samples. HPRT1 was used as a housekeeping gene. Error bars represent \pm SD (n=3).




Figure S2. (A) Design of AP2i and AP2i-R3 targeting AP2 binding sequence in *HER2* promoter region (chemical structures are shown in Fig. S3). (B) Schematic illustration of *HER2* repression by AP2i-R3. (C) Relative expression level of *HER2* in SKBR-3 cells treated with AP2i and AP2i-R3 for 48 hours. Mean values calculated from three culture wells are shown and each value is normalized to the control samples. *ACTB* was used as a housekeeping gene. Error bars represent \pm SD (n = 3).

Characterization data of synthesized compounds

1. SOX2i-R3










Figure S3. Chemical structure, HPLC chart and mass spectra of compound 1-7.

2. SOX2i-R3-TAMRA



(Continued) Figure S3. Chemical structure, HPLC chart and mass spectra of compound 1-7.


3. SOX2i



Analytical HPLC $t_R = 16.9$ min


MALDI-TOF MS m/z for $C_{75}H_{92}N_{27}O_{14}^+$

$[M + H]^+$ calcd 1594.73, found 1594.64



(Continued) Figure S3. Chemical structure, HPLC chart and mass spectra of compound 1-7.



4. SOX2i-TAMRA



Analytical HPLC t_R = 18.2 min




MALDI-TOF MS m/z for $C_{102}H_{117}N_{30}O_{18}^+$

$[M + H]^+$ calcd 2049.92, found 2049.91




(Continued) Figure S3. Chemical structure, HPLC chart and mass spectra of compound 1-7.

5. Ctrl-R3



(Continued) Figure S3. Chemical structure, HPLC chart and mass spectra of compound 1-7.



6. AP2i



Analytical HPLC $t_R = 17.5$ min




MALDI-TOF MS m/z for $C_{72}H_{89}N_{30}O_{14}^+$

$[M + H]^+$ calcd 1597.72, found 1598.02



(Continued) Figure S3. Chemical structure, HPLC chart and mass spectra of compound 1-7.

7. AP2i-R3



(Continued) Figure S3. Chemical structure, HPLC chart and mass spectra of compound 1-7.

Primers used for qPCR

Table S1. The primer list for qPCR experiments

primer	Sequence
<i>HPRT1</i> forward	5'- GGCGAACCTCTCGGCTTTC
<i>HPRT1</i> reverse	5'- TCATCACTAATCACGACGCCA
<i>SOX2</i> forward	5'- GGGAAATGGGAGGGGTGCAAAAGAGG
<i>SOX2</i> reverse	5'- TTGCGTGAGTGTGGATGGGATTGGTG
<i>18S</i> forward	5'- AAACGGCTACCACATCCAAG
<i>18S</i> reverse	5'- CCTCCAATGGATCCTCGTTA
<i>Nanog</i> forward	5'- AATACCTCAGCCTCCAGCAGATG
<i>Nanog</i> reverse	5'- TCGGTCACACCATTGCTATTCTTC
<i>FBXO15</i> forward	5'- TGGCTGTGACAGACTCATTCGG
<i>FBXO15</i> reverse	5'- GATAGTAGCCGAGCCTAATGTGC
<i>HER2</i> forward	5'- GAGCACCCAAGTGTGCAC
<i>HER2</i> reverse	5'- TTGGTTGTGAGCGATGAG
<i>ACTB</i> forward	5'- CAATGTGGCCGAGGACTTTG
<i>ACTB</i> reverse	5'- CATTCTCCTTAGAGAGAAGTGG

References

1. Y. Sawatani, G. Kashiwazaki, A. Chandran, S. Asamitsu, C. Guo, S. Sato, K. Hashiya, T. Bando, H. Sugiyama, *Bioorganic Med. Chem.* 2016, **24**, 3603.
2. J. Syed, G. N. Pandian, S. Sato, J. Taniguchi, A. Chandran, K. Hashiya, T. Bando, H. Sugiyama, *Chem. Biol.* 2014, **21**, 1370.